Recent progress in the pharmacotherapy of cancer pain

Expert Review of Anticancer Therapy

Volumn 1, Issue 3, 2001, Pages 487-494

  Mercadante, Sebastiano ^a  

^a LA MADDALENA CANCER CENTER   (Italy)

Author keywords

Adjuvants; Cancer pain; NSAIDs; Opioid; Opioid response; Pain mechanisms

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BUPRENORPHINE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLONAZEPAM; DIAMORPHINE; FENTANYL; FENTANYL CITRATE; GABAPENTIN; GLUCOCORTICOID; HYDROMORPHONE; LIDOCAINE; LOCAL ANESTHETIC AGENT; METHADONE; MEXILETINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NIMODIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PHENYTOIN; SODIUM CHANNEL BLOCKING AGENT; SUFENTANIL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

ANALGESIA; ANALGESIC ACTIVITY; CANCER PAIN; CHILD; CONSTIPATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; HYPOTENSION; NONHUMAN; RAT; REVIEW; URINE RETENTION; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

EID: 0035557974     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.1.3.487     Document Type: Review

References (45)

1. Morphine and alternative opioids in cancer pain
2. Treatment and outcome of cancer pain in advanced cancer patients followed at home
3. Predictive factors and opioid responsiveness in cancer pain
4. Opioid poorly responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness
5. Factors influencing the opioid response in advanced cancer patients with pain followed at home: The effects of age and gender
6. Opioid responsiveness - Primary diagnosis relationship in advanced cancer patients followed at home
7. Breakthrough pain in cancer patients: Pathophysiology and treatment
8. Opioid poorly responsive cancer pain. Part 1. Clinical considerations
9. Alternatives to oral morphine in cancer pain
10. Costs are a further barrier to cancer pain management
11. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain
12. Opioid rotation in cancer pain: Rationale and clinical aspects
13. Strategies to manage the adverse effects of oral morphine: An evidence-based report
14. The role of morphine metabolites in cancer pain
15. Opioid rotation for toxicity reduction in terminal cancer patients
16. Changing pattern of agitated impaired mental status in patients with advanced cancer: Association with cognitive monitoring, hydration and opioid rotation
17. A retrospective comparison of dose ratios between methadone, hydromorphone and morphine
18. Switching from morphine to oral metadone in treating cancer pain: What is the equianalgesic dose ratio?
19. An update on the clinical use of methadone for cancer pain
20. Methadone in cancer pain
21. Comments on Ripamonti
22. Patient-controlled analgesia with oral methadone in cancer patients: Preliminary report
23. Switching form morphine to methadone to improve analgesia and tolerability in cancer patients. A prospective study
24. Rapid switching from methadone to morphine in cancer patients with poor response to morphine
25. Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine
26. Long-term observations of patients receiving transdermal fentanyl after a randomized trial
27. Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration
28. Oral transmucosal fentanyl citrate: Randomised, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients
29. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain
30. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: A controlled dose titration study
31. Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR)
32. Long-term safety or oral transmucosal fentanyl citrate for breakthrough cancer pain
33. Amitriptyline affectively relieves neuropathic pain following treatment of breast cancer
34. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus
35. Gabapentin for the treatment of postherpetic neuralgia. A randmized controlled trial
36. Gabapentin as adjuvant to opioid analgesia for neuropathic cancer pain
37. The use of steroids in advanced cancer patients followed at home
38. The use of NSAIDs in cancer pain
39. Nonsteroidal anti-inflammatory drugs for cancer pain: Comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage
40. Malignant bone pain: Pathophysiology and treatment
41. Pamidronate in incident pain due to bone metastases
42. Ketamine in cancer pain: An update
43. The analgesic effect of ketamine in cancer patients on opioid therapy: A randomized, controlled, double-blind, cross-over, double-dose study
44. Drug interactions in human neuropathic pain pharmacotherapy
45. Drug interactions in palliative care